These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 35802197)

  • 1. Triple therapy in biliary tract cancers: GemOX plus immune checkpoint inhibitor in combination with lenvatinib or NGS-guided targeted therapy.
    Dong X; Zhang Z; Zhang Q; Chen L; Cao G; Liu C; Song T; Lu W; Zhang W
    J Cancer Res Clin Oncol; 2023 May; 149(5):1917-1927. PubMed ID: 35802197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lenvatinib combined with PD-1 inhibitor plus Gemox chemotherapy versus plus HAIC for advanced biliary tract cancer.
    Zhang T; Zhu C; Zhang N; Zhang L; Wang S; Xun Z; Xu Y; Yang X; Lu X; Zhao H
    Int Immunopharmacol; 2024 Mar; 129():111642. PubMed ID: 38325044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of lenvatinib combined with PD-1/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer.
    Zhu C; Xue J; Wang Y; Wang S; Zhang N; Wang Y; Zhang L; Yang X; Long J; Yang X; Sang X; Zhao H
    Front Immunol; 2023; 14():1109292. PubMed ID: 36742297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Next-generation sequencing-guided molecular-targeted therapy and immunotherapy for biliary tract cancers.
    Zhang W; Shi J; Wang Y; Zhou H; Zhang Z; Han Z; Li G; Yang B; Cao G; Ke Y; Zhang T; Song T; QiangLi
    Cancer Immunol Immunother; 2021 Apr; 70(4):1001-1014. PubMed ID: 33095329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of lenvatinib combined with anti-PD-1 antibodies plus GEMOX chemotherapy as non-first-line systemic therapy in advanced gallbladder cancer.
    Tan Y; Liu K; Zhu C; Wang S; Wang Y; Xue J; Ning C; Zhang N; Chao J; Zhang L; Long J; Yang X; Zeng D; Zhao L; Zhao H
    Cancer Immunol Immunother; 2024 Oct; 73(12):240. PubMed ID: 39358463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lenvatinib Plus Programmed Cell Death Protein-1 Inhibitor Beyond First-Line Systemic Therapy in Refractory Advanced Biliary Tract Cancer: A Real-World Retrospective Study in China.
    Shi C; Li Y; Yang C; Qiao L; Tang L; Zheng Y; Chen X; Qian Y; Yang J; Wu D; Xie F
    Front Immunol; 2022; 13():946861. PubMed ID: 35967452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. mFOLFOX-HAIC+lenvatinib+PD-1 inhibitors versus GC/GS/GEMOX chemotherapy as a first line therapy for advanced biliary tract cancer: A single-center retrospective cohort study.
    Sun Z; Xu H; Yang L; Wang X; Shu B; Yang M; Ren Z; Xiang C; Zhang Y; Yang S
    Biosci Trends; 2024 Oct; ():. PubMed ID: 39401897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial.
    Chen X; Wu X; Wu H; Gu Y; Shao Y; Shao Q; Zhu F; Li X; Qian X; Hu J; Zhao F; Mao W; Sun J; Wang J; Han G; Li C; Xia Y; Seesaha PK; Zhu D; Li H; Zhang J; Wang G; Wang X; Li X; Shu Y
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33172881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic arterial infusion of GEMOX plus systemic gemcitabine chemotherapy combined with lenvatinib and PD-1 inhibitor in large unresectable intrahepatic cholangiocarcinoma.
    Ni JY; Sun HL; Guo GF; Zhou X; Wei JX; Xu LF
    Int Immunopharmacol; 2024 Oct; 140():112872. PubMed ID: 39121605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer.
    Chen JS; Hsu C; Chiang NJ; Tsai CS; Tsou HH; Huang SF; Bai LY; Chang IC; Shiah HS; Ho CL; Yen CJ; Lee KD; Chiu CF; Rau KM; Yu MS; Yang Y; Hsieh RK; Chang JY; Shan YS; Chao Y; Chen LT;
    Ann Oncol; 2015 May; 26(5):943-949. PubMed ID: 25632066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study.
    Zhu C; Li H; Yang X; Wang S; Wang Y; Zhang N; Wang Y; Xue J; Zhang L; Ning C; Yang X; Xun Z; Chao J; Long J; Sang X; Zhu Z; Zhao H
    Cancer Immunol Immunother; 2023 Sep; 72(9):2949-2960. PubMed ID: 37247023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic treatment of advanced or recurrent biliary tract cancer.
    Zhang W; Zhou H; Wang Y; Zhang Z; Cao G; Song T; Zhang T; Li Q
    Biosci Trends; 2020 Nov; 14(5):328-341. PubMed ID: 32830166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study.
    Shi GM; Huang XY; Wu D; Sun HC; Liang F; Ji Y; Chen Y; Yang GH; Lu JC; Meng XL; Wang XY; Sun L; Ge NL; Huang XW; Qiu SJ; Yang XR; Gao Q; He YF; Xu Y; Sun J; Ren ZG; Fan J; Zhou J
    Signal Transduct Target Ther; 2023 Mar; 8(1):106. PubMed ID: 36928584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Camrelizumab plus oxaliplatin-based chemotherapy as first-line therapy for advanced biliary tract cancer: A multicenter, phase 2 trial.
    Chen X; Qin S; Gu S; Ren Z; Chen Z; Xiong J; Liu Y; Meng Z; Zhang X; Wang L; Zhang X; Zou J
    Int J Cancer; 2021 Dec; 149(11):1944-1954. PubMed ID: 34309846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study.
    Feng K; Liu Y; Zhao Y; Yang Q; Dong L; Liu J; Li X; Zhao Z; Mei Q; Han W
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32487569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective cohort study on the efficacy and safety for combination therapy of immunotherapy, targeted agent, and chemotherapy versus immunochemotherapy or chemotherapy alone in the first-line treatment of advanced biliary tract carcinoma.
    Zeng J; Ma J; Zeng Z; Yang L; Jiang Y; Mo N; Ma F; Liu C; Li R; Tang J; Qin S; Jiang H
    J Gastrointest Oncol; 2023 Apr; 14(2):758-767. PubMed ID: 37201053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.
    Yoon JG; Kim MH; Jang M; Kim H; Hwang HK; Kang CM; Lee WJ; Kang B; Lee CK; Lee MG; Chung HC; Choi HJ; Park YN
    Hepatology; 2021 Oct; 74(4):1914-1931. PubMed ID: 33884649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study.
    Gruenberger B; Schueller J; Heubrandtner U; Wrba F; Tamandl D; Kaczirek K; Roka R; Freimann-Pircher S; Gruenberger T
    Lancet Oncol; 2010 Dec; 11(12):1142-8. PubMed ID: 21071270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
    Abdel-Rahman O; Elsayed Z; Elhalawani H
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study.
    Zhu AX; Meyerhardt JA; Blaszkowsky LS; Kambadakone AR; Muzikansky A; Zheng H; Clark JW; Abrams TA; Chan JA; Enzinger PC; Bhargava P; Kwak EL; Allen JN; Jain SR; Stuart K; Horgan K; Sheehan S; Fuchs CS; Ryan DP; Sahani DV
    Lancet Oncol; 2010 Jan; 11(1):48-54. PubMed ID: 19932054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.